<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Baraliakos, Xenofon</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Inflammation and Fatty Degeneration in New Bone Formation in Patients with AS Treated with Anti-TNF Agents</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">When the inflammation of ankylosing spondylitis (AS) subsides, it may be replaced by repair tissue and fatty lesions, a process that leads to osteoproliferation and development of syndesmophytes. This article presents results from the European Ankylosing Spondylitis Infliximab Cohort [EASIC] study, an open-label extension of the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy [ASSERT]. The objective of the EASIC study was to directly compare the effect of inflammation and fatty degeneration on the development of syndesmophytes in patients with AS after 5 years of anti-TNF therapy.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>